Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.drudis.2022.06.001 http://scihub22266oqcxt.onion/10.1016/j.drudis.2022.06.001 35667629!9162932!35667629     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Drug+Discov+Today 2022 ; 27 (9): 2411-2414 Nephropedia Template TP {{tp|p=35667629|t=2022. Multiple deadlocks in the development of nonprofit drugs |pdf=|usr=}}{{35667629}} gab.com Text Multiple deadlocks in the development of nonprofit drugs JO: Drug Discov Today http://www.kidney.de/pget.php?&tw=1&pmid=35667629 #FOAvip The current Coronavirus 2019 (COVID-19) pandemic has shown us that the pharmaceutical research community can organize and administer large nonprofit clinical trials (RECOVERY and SOLIDARITY) and achieve the swift development of common, unpatentable drugs for a new indication: in this case an old, inexpensive drug, dexamethasone, for COVID-19. Why is it that such nonprofit efforts are so rare and are not organized as a systemic, routine part of drug development in the public interest? Based on my own experience with repurposing the alcohol-abuse drug disulfiram (Antabuse) for cancer, I identify at least four serious deadlocks to development of nonprofit drugs. All of these obstacles should be addressed to leverage the potential of the COVID-19 pandemic for better future healthcare systems in all countries around the world. Twit Text FOAVip Multiple deadlocks in the development of nonprofit drugs ????Drug Discov Today http://www.kidney.de/pget.php?&tw=1&pmid=35667629 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=35667629 #FOAvip English Wikipedia <ref>{{Cite pmid|35667629}}</ref> Multiple deadlocks in the development of nonprofit drugs #MMPMID35667629 Cvek B Drug Discov Today 2022[Sep]; 27 (9): 2411-2414 PMID35667629show ga The current Coronavirus 2019 (COVID-19) pandemic has shown us that the pharmaceutical research community can organize and administer large nonprofit clinical trials (RECOVERY and SOLIDARITY) and achieve the swift development of common, unpatentable drugs for a new indication: in this case an old, inexpensive drug, dexamethasone, for COVID-19. Why is it that such nonprofit efforts are so rare and are not organized as a systemic, routine part of drug development in the public interest? Based on my own experience with repurposing the alcohol-abuse drug disulfiram (Antabuse) for cancer, I identify at least four serious deadlocks to development of nonprofit drugs. All of these obstacles should be addressed to leverage the potential of the COVID-19 pandemic for better future healthcare systems in all countries around the world. |*COVID-19[MESH] |*Pandemics[MESH] |Delivery of Health Care[MESH] |Disulfiram[MESH] |Humans[MESH]Multiple deadlocks in the development of nonprofit drugs (epmc).pdf DeepDyve Pubget Overpricing